224 related articles for article (PubMed ID: 20684152)
21. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
22. A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.
Chahin S; Berger JR
J Neurovirol; 2015 Dec; 21(6):623-31. PubMed ID: 25404234
[TBL] [Abstract][Full Text] [Related]
23. Efalizumab discontinuation: a practical strategy.
Pugashetti R; Koo J
J Dermatolog Treat; 2009; 20(3):132-6. PubMed ID: 19459081
[TBL] [Abstract][Full Text] [Related]
24. Progressive multifocal leukoencephalopathy complicating Waldenström's macroglobulinaemia.
Ng C; Slavin MA; Seymour JF
Leuk Lymphoma; 2003 Oct; 44(10):1819-21. PubMed ID: 14692541
[TBL] [Abstract][Full Text] [Related]
25. Progressive multifocal leukoencephalopathy associated with fumaric acid esters treatment in psoriasis patients.
Balak DMW; Hajdarbegovic E; Bramer WM; Neumann HAM; Thio HB
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1475-1482. PubMed ID: 28322482
[TBL] [Abstract][Full Text] [Related]
26. Progressive multifocal leukoencephalopathy.
Weissert R
J Neuroimmunol; 2011 Feb; 231(1-2):73-7. PubMed ID: 20937530
[TBL] [Abstract][Full Text] [Related]
27. A Kidney Transplant Recipient With Fulminant Progressive Multifocal Leukoencephalopathy-Immune Reconstitution Inflammatory Syndrome: A Rare Clinical Outcome and Review of the Literature.
Kirincich J; Basic-Jukic N; Radic J; Lovric-Kujundzic S; Kastelan Z
Exp Clin Transplant; 2020 Apr; 18(2):242-246. PubMed ID: 31580233
[TBL] [Abstract][Full Text] [Related]
28. Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine.
Alstadhaug KB; Fykse Halstensen R; Odeh F
J Clin Virol; 2017 Mar; 88():17-20. PubMed ID: 28095350
[TBL] [Abstract][Full Text] [Related]
29. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies.
Major EO
Annu Rev Med; 2010; 61():35-47. PubMed ID: 19719397
[TBL] [Abstract][Full Text] [Related]
30. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?
Molloy ES; Calabrese LH
Autoimmun Rev; 2008 Dec; 8(2):144-6. PubMed ID: 18700172
[TBL] [Abstract][Full Text] [Related]
31. [New trends in progressive multifocal leukoencephalopathy].
Gasnault J; Taoufik Y
Rev Neurol (Paris); 2006 Jan; 162(1):43-56. PubMed ID: 16446622
[TBL] [Abstract][Full Text] [Related]
32. The pathogenesis of progressive multifocal leukoencephalopathy.
Berger JR; Khalili K
Discov Med; 2011 Dec; 12(67):495-503. PubMed ID: 22204766
[TBL] [Abstract][Full Text] [Related]
33. JC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the hematogenous route.
Van Loy T; Thys K; Ryschkewitsch C; Lagatie O; Monaco MC; Major EO; Tritsmans L; Stuyver LJ
J Virol; 2015 Jan; 89(2):1340-7. PubMed ID: 25392214
[TBL] [Abstract][Full Text] [Related]
34. JC virus DNA in cerebrospinal fluid of human immunodeficiency virus-infected patients: predictive value for progressive multifocal leukoencephalopathy.
McGuire D; Barhite S; Hollander H; Miles M
Ann Neurol; 1995 Mar; 37(3):395-9. PubMed ID: 7695239
[TBL] [Abstract][Full Text] [Related]
35. [Progressive multifocal leukoencephalopathy: a complication in chronic B-cell lymphatic leukaemia].
van Kernebeek CR; Ünal E; Schaar CG; Bienfait HP
Ned Tijdschr Geneeskd; 2020 Mar; 164():. PubMed ID: 32267644
[TBL] [Abstract][Full Text] [Related]
36. Progressive multifocal leukoencephalopathy in a kidney transplant recipient after conversion to mycophenolic acid therapy.
Manfro RC; Vedolin L; Cantarelli M; Oppitz P; Antunes AC; Rieder CR
Transpl Infect Dis; 2009 Apr; 11(2):189-90. PubMed ID: 19210690
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy.
Bossolasco S; Calori G; Moretti F; Boschini A; Bertelli D; Mena M; Gerevini S; Bestetti A; Pedale R; Sala S; Sala S; Lazzarin A; Cinque P
Clin Infect Dis; 2005 Mar; 40(5):738-44. PubMed ID: 15714422
[TBL] [Abstract][Full Text] [Related]
38. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
Cutter GR; Stüve O
Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
[TBL] [Abstract][Full Text] [Related]
39. [Progressive multifocal leukoencephalopathy--epidemiology, clinical pictures, diagnosis and therapy].
Kishida S
Brain Nerve; 2007 Feb; 59(2):125-37. PubMed ID: 17380777
[TBL] [Abstract][Full Text] [Related]
40. Fatal progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma treated with rituximab.
Paues J; Vrethem M
J Clin Virol; 2010 Aug; 48(4):291-3. PubMed ID: 20558102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
